SBI Securities’s Silence Therapeutics SLN Stock Holding History

SBI Securities’s Portfolio SLN Stock Details SLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$307	Hold	28	–	–	﹤0.01%	3194
2026 Q1	$148	Hold	28	–	–	﹤0.01%	3313
2025 Q4	$170	Sell	28 -1	-3%	-$6	﹤0.01%	3261
2025 Q3	$151	Buy	29 +1	+4%	+$6	﹤0.01%	3404
2025 Q2	$162	Hold	28	–	–	﹤0.01%	3380
2025 Q1	$79	Hold	28	–	–	﹤0.01%	3523
2024 Q4	$193	Buy	+28	New	+$361	﹤0.01%	3256

Other funds holding SLN

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

SBI Securities's SLN Position: Q2 2026 in Review

SBI Securities held its Silence Therapeutics (SLN) position steady in Q2 2026 at 28 shares worth $307. The position accounts for ﹤0.01% of the portfolio, ranked #3194.

SBI Securities first reported a position in SLN in Q4 2024 and has held it in 7 quarters since. 4 funds tracked by Wall St. Rank hold SLN as of Q2 2026.

SBI Securities held 28 shares of Silence Therapeutics worth $307 as of Q2 2026.
SBI Securities left its Silence Therapeutics share count unchanged in Q2 2026.
Silence Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3194 holding.
SBI Securities first reported a position in Silence Therapeutics in Q4 2024 and has held it in 7 quarters since.
4 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.